← 홈

프로그램 비교

타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-5 · 마지막 9월 2일

현재 선택: 1 · 임상 갱신 필요 1

프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.

API CSV26행 · 1개 프로그램

표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.

항목
AntibodyLimited DatastalePhase 3
BAT (Best Available Therapy, Best Available Therapy (BAT))
Incyte Corporation·Relapsing Multiple Sclerosis
240 trials·t½ 52 h
Overview
Program
Best Available Therapy (BAT)
Overview
Company
Incyte Corporation
Overview
Modality
ANTIBODY
Overview
Target
Relapsing Multiple Sclerosis
Overview
Indication
Chronic Graft-versus-host-disease
Overview
Phase
PHASE_3
Overview
Status
RECRUITING
Overview
Content status
Limited Data
Overview
Data Confidence
Data Confidence · Low
Overview
Development Signal
Development Signal · Emerging
Overview
Approval status
Investigational
MoA
Mechanism
inhibits high-fat diet-induced obesity by regulating the ROS/JNK/BRD4/SHP2 signaling pathway
MoA
Biomarker
biomarker data support an endotype-driven approach: higher total immunoglobulin E (IgE) is generally associat
PK/PD
Half-life
52 h
PK/PD
Species
Mouse
PK/PD
Animal (cat.)
Mouse
PK/PD
Experiment
PK
Toxicology
Species
Mouse
Toxicology
Animal (cat.)
Mouse
Toxicology
Major finding
Fat depot-specific accumulation of benzo(a)pyrene metabolites in rats fed with western diet and its implications for colon cancer.. Obesity is one of the factors that potentiate the development of colorectal cancer (CRC). Our previous studies using a rat model, the Polyposis In the Rat Colon (PIRC) kindred type revealed that compared to regular diet (RD), the Western diet (WD) accelerated the prog…
Clinical
Safety signal
Fat depot-specific accumulation of benzo(a)pyrene metabolites in rats fed with western diet and its implications for colon cancer.. Obesity is one of the factors that potentiate the development of colorectal cancer (CRC). Our previous studies using a rat model, the Polyposis In the Rat Colon (PIRC) kindred type revealed that compared to regular diet (RD), the Western diet (WD) accelerated the prog…
Clinical
Selected reported efficacy
49.7%
Clinical
Result source
ClinicalTrials.gov NCT03112603
Clinical
Program phase
PHASE_3
Clinical
Trial activity
No active/completed counts
Clinical
Trial ref
NCT03112603